**Core tip:** Peutz-Jeghers syndrome (PJS) is currently considered an autosomal dominant inherited disease caused by germline mutations of the *LKB1/STK11* gene. Gastrointestinal hamartoma polyps are one of the most common clinical manifestations. In order to investigate the mutation status of these familiar genetically-related genes in PJS hamartoma polyp tissues, high-throughput sequencing was used to analyze the mutations of related genes in PJS hamartoma polyps. In addition, the relationships between the mutation status and the clinical pathological data of PJS are discussed.

INTRODUCTION
============

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant inherited disease. The main manifestation of PJS is hamartoma polyps throughout the gastrointestinal tract\[[@B1],[@B2]\]. It is believed\[[@B3]-[@B5]\] that germline mutations of the tumor suppressor gene *LKB1/STK11* are involved in the etiology of PJS. The encoded product of *LKB1/STK11* gene is a serine/threonine protein kinase which is widely distributed in various tissues\[[@B6],[@B7]\] and plays an important role in regulating cellular energy metabolism, chromatin remodeling, DNA damage response, cell cycle arrest, p53-mediated apoptosis, as well as cell polarization\[[@B8]-[@B10]\]. Although PJS is a rare clinical disease, these hamartoma polyps can cause serious clinical damage and obvious heterogeneity of clinical phenotypes. Therefore, it is necessary to study the mutations of *LKB1/STK11* gene and other hereditary colorectal tumor-associated genes in PJS hamartoma polyp tissue to investigate the correlation between genotype and phenotype. Twenty patients with PJS were randomly selected for this study, and were treatment in the Air Force Medical Center (former Air Force General Hospital) PLA between 2008 and 2017. Fourteen genetically-related genes (*APC, AXIN2, BMPR1A, EPCAM, MLH1, MLH3, MSH2, MSH6, MUTYH, PMS1, PMS2, PTEN, SMAD4, LKB1/STK11*) were sequenced in hamartoma polyp tissue from these patients using next-generation sequencing technology to determine the mutation status of these familiar genetically-related genes in PJS hamartoma polyp tissues, and examine the relationship between the mutation status of these genes and the clinical pathological data of PJS.

MATERIALS AND METHODS
=====================

Clinical data
-------------

Twenty patients with PJS were randomly selected for this study, and were treated in the Air Force Medical Center (former Air Force General Hospital) PLA between 2008 and 2017. All patients met the diagnostic criteria for PJS recommended by the National Comprehensive Cancer Network\[[@B11]\], and complied with the guidelines of the Declaration of Helsinki. The guardians of children and adult patients were informed of the purpose of the study, and signed an informed consent form. Their complete clinicopathological data were recorded, and hamartoma polyp tissue samples were obtained and preserved, excluding cancerous polyps (Table [1](#T1){ref-type="table"}).

###### 

Clinicopathological data of enrolled patients with Peutz-Jeghers syndrome

  **Case No**.   **Onset time of pigment spots (yr)**   **Gender**   **Family history or not (detail)**   **Load of gastric polyps**   **Maximum diameter of gastric polyps (mm)**   **Load of duodenal and small intestinal polyps**   **Maximum diameter of duodenal and small intestinal polyps (mm)**   **Load of colorectal polyps**   **Maximum diameter of colorectal polyps (mm)**   **Number of hospitalization times**   **Number of operation times**   **Number of intervention times**
  -------------- -------------------------------------- ------------ ------------------------------------ ---------------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------- ------------------------------- ------------------------------------------------ ------------------------------------- ------------------------------- ----------------------------------
  1              0                                      Male         Yes (Father)                         0                            0                                             1-10                                               30                                                                  Unknown                         Unknown                                          1                                     1                               3
  2              0                                      Male         No                                   1-10                         10                                            31-40                                              80                                                                  11-20                           70                                               3                                     1                               4
  3              7                                      Female       Yes (Father)                         1-10                         6                                             21-30                                              25                                                                  Unknown                         Unknown                                          1                                     1                               4
  4              2                                      Male         No                                   11-20                        17                                            1-10                                               25                                                                  1-10                            40                                               1                                     1                               4
  5              10                                     Male         Yes (Son)                            1-10                         5                                             51-60                                              50                                                                  41-50                           25                                               5                                     3                               12
  6              1                                      Male         Yes (Mother)                         1-10                         5                                             1-10                                               35                                                                  1-10                            35                                               2                                     1                               3
  7              1                                      Male         No                                   1-10                         23                                            1-10                                               50                                                                  Unknown                         Unknown                                          1                                     0                               2
  8              1                                      Male         Yes (Grandmother and mother)         0                            0                                             Unknown                                            Unknown                                                             51-60                           70                                               1                                     4                               20
  9              7                                      Male         Yes (Father)                         0                            0                                             11-20                                              60                                                                  21-30                           12                                               1                                     1                               9
  10             13                                     Female       No                                   0                            0                                             1-10                                               40                                                                  1-10                            10                                               3                                     4                               9
  11             2                                      Male         No                                   1-10                         8                                             1-10                                               25                                                                  1-10                            6                                                2                                     0                               4
  12             0                                      Female       No                                   1-10                         15                                            41-50                                              60                                                                  11-20                           50                                               2                                     4                               9
  13             5                                      Female       Yes (Father and brother)             21-30                        15                                            41-50                                              60                                                                  21-30                           60                                               4                                     2                               9
  14             18                                     Female       No                                   21-30                        5                                             11-20                                              30                                                                  1-10                            6                                                2                                     1                               5
  15             0.8                                    Female       Yes (Father)                         1-10                         6                                             1-10                                               6                                                                   0                               0                                                2                                     0                               4
  16             2                                      Male         Yes (Father)                         21-30                        20                                            31-40                                              45                                                                  51-60                           45                                               2                                     7                               21
  17             4                                      Female       Yes (Son)                            Unknown                      Unknown                                       21-30                                              30                                                                  1-10                            30                                               1                                     1                               5
  18             0                                      Male         No                                   1-10                         15                                            Unknown                                            Unknown                                                             1-10                            20                                               1                                     0                               2
  19             5                                      Female       No                                   0                            0                                             11-20                                              20                                                                  Unknown                         Unknown                                          1                                     2                               7
  20             4                                      Female       Yes (Sister)                         1-10                         50                                            21-30                                              50                                                                  Unknown                         Unknown                                          1                                     0                               7

Experimental method
-------------------

The genomic DNA was extracted from PJS polyp tissue using the QIAamp DNA FFPE Tissue Kit microsample genomic DNA extraction kit, and the experiment was performed according to the kit instructions (QIAamp Tissue DNA FFPE Tissue Kit, QIAGEN, QIAGEN Strasse 1407124 Hilden, Germany).

A normalized cDNA library was built using Ion AmpliSeq Library Kit 2.0 according to the manufacturer's instructions. Two types of Ion Ampliseq custom panels: IAD72340_182_pool 1 and IAD72340_182_pool 2, were used as multiplex PCR primers, which covered all exons and exon-intron junctions of 14 common hereditary colorectal tumor-associated genes (*APC, AXIN2, BMPR1A, EPCAM, MLH1, MLH3, MSH2, MSH6, MUTYH, PMS1, PMS2, PTEN, SMAD4, LKB1/STK11*). After amplification, the paramagnetic particle method (AMPure XP Reagent, Beckman, United States) was used to purify the library. The library was quantitatively detected using fluorescence quantitative PCR (ViiA 7 Dx, Life Technologies Holdings PTE Ltd Block, Singapore city, Singapore). Template preparation (Ion OneTouch2) and template enrichment (Ion OneTouch ES) was then performed using an automated template preparation instrument (Ion OneTouch^TM^ 2 system). High-throughput sequencing was performed using sequencer Ion PGM (Life Technologies).

Quality control sequencing data with a target capture rate \> 75%, coverage uniformity \> 80%, and average sequencing depth \> 150× were used as parameters, and the sequencing results were analyzed using Torrent Suite software (Life Technologies; v5.0.4) and compared using the hg19 Human reference genome. The detected gene mutations were annotated with Ion Reporter software (<https://ionreporter.lifetechnologies.com/ir/secure/home.html>) and ANNOVAR package software (<http://wannovar.wglab.org/>).

Candidate verification sites were screened according to the mutation frequency. The dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 Genomes Project (<http://ftp.Ncbi.nih.gov/>) and the genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org/>) were used in the population frequency database. Suspect or clear pathogenic sites included in HGMD (version 2017.03, <http://www.hgmd.cf.ac.uk/ac/index.php>) and database frequency \< 0.01, and between 0.01 and 0.05 were retained for verification.

Prime3 online software (<http://bioinfo.ut.ee/primer3/>) was used to design PCR primers for candidate verification sites\[[@B12]\]. The designed primers were synthesized by Xi\'an Qingke Biological Company. The primers were detected and purified after amplification, and were sequenced using the AB 3500xl Dx automatic DNA sequencer (Xi\'an Qingke Biological Co., Ltd.). The results verified the preliminary screening of candidate sites.

Protein functional prediction of mutant genes using software Polymorphism Phenotyping v2 (PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/index.shtml>), MutationTaster (<http://www.mutationtaster.org/>), Functional Analysis through Hidden Markov Models (FATHMM, <http://fathmm.biocompute.org.uk/index.html>) and Mendelian Clinically Applicable Pathogenicity (M-CAP, <http://bejerano.stanford.edu/MCAP/>) for primary screening candidate sites verified by first-generation sequencing, and software GERP++ (<http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html>) and PhyloP (<http://compgen.bscb.cornell.edu/phast>) were used to make conservative predictions of amino acid evolution. Protein models were built using SWISS MODEL (<https://www.swissmodel.expasy.org/>) online software.

Statistical analyses
--------------------

Statistical analysis of the data was performed using the SPSS 24.0 software package. The normal distribution measurement data are expressed as the mean *±* SD, and the non-normal distribution data are described as the median (interquartile range *Q*). The number of statistical data and the composition ratio were compared. The *χ*^2^ test or Fisher\'s exact probability method was used to compare the composition of the groups. In the quantitative data, the time of occurrence of dark spots, the interval between the appearance of dark spots and abdominal symptoms, the age at initial diagnosis and the maximum diameter of polyps, *etc*. were determined. The inter-group comparison of the state distribution data was performed using the Mann-Whitney *U* test or Kruskal-Wallis *H* test. *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Mutations of LKB1/STK11 gene
----------------------------

In this patient group, *LKB1/STK11* gene mutations were detected in 16 of 20 cases, with 14 types of mutations, of which 8 new mutations were detected. According to the prediction of Mutationtaster software, 8 types of protein truncation mutations were found in 10 cases (2 types of nonsense mutations detected in 3 cases, 6 types of frameshift mutations in 7 cases). Among them, the frameshift mutations can cause truncation protein mutations (Table [2](#T2){ref-type="table"}). These mutations can change protein function and the prediction of amino acid evolution conservatiion is shown in Table [3](#T3){ref-type="table"}.

###### 

Mutation status of *LKB1/STK11* gene

  **Case No**.   **Allele**      **Mutation type**      **Exon/intron**                       **Amino acid change**   **Base change**                       **New mutation**
  -------------- --------------- ---------------------- ------------------------------------- ----------------------- ------------------------------------- ------------------
  1              Heterozygosis   Missense               4                                     p.L167R                 c.500T\>G                             No
  2              Heterozygosis   Nonsense               1                                     p.K84\*                 c.250A\>T                             No
  3              Heterozygosis   Frameshift deletion    5                                     p.A241Vfs\*46           c.722delC                             Yes
  4              Homozygous      Frameshift insertion   3                                     p.Q152Pfs\*11           c.454_455insC                         Yes
  5              Heterozygosis   Frameshift insertion   1                                     p.Y49Afs\*4             c.144_145insGCAAG                     Yes
  6              Heterozygosis   Missense               5                                     p.S240W                 c.719C\>G                             No
  7              Heterozygosis   Frameshift deletion    1                                     p.K82Rfs\*14            c.243delG                             Yes
  8              Heterozygosis   Cleavage site          5-6[1](#T2FN1){ref-type="table-fn"}   /                       c.734+1G\>A                           Yes
  10             Heterozygosis   Cleavage site          3-4[1](#T2FN1){ref-type="table-fn"}   /                       c.464+1G\>T                           Yes
  13             Homozygous      Frameshift deletion    3                                     p.E145Gfs\*10           c.426_448delCGTGCCGGAGAAGCGTTTCCCAG   No
  14             Heterozygosis   Nonsense               1                                     p.K84\*                 c.250A\>T                             No
  16             Heterozygosis   Frameshift insertion   1                                     p.Y49Afs\*4             c.144_145insGCAAG                     No
  17             Heterozygosis   Cleavage site          4-5[1](#T2FN1){ref-type="table-fn"}   /                       c.598-1G\>A                           Yes
  18             Heterozygosis   Nonsense               1                                     p.Y49\*                 c.147C\>G                             No
  19             Heterozygosis   Frameshift deletion    2                                     p.K122Afs\*40           c.363_364delGA                        Yes
  20             Homozygosis     Cleavage site          3-4[1](#T2FN1){ref-type="table-fn"}   /                       c.464+1G\>A                           No

Mutation is located in the intron.

###### 

Prediction of protein function and amino acid evolution conservation of *LKB1/STK11*

  **Case No**.   **Polyphen-2**   **Mutation taster**   **FATHMM**   **M-CAP**    **GERP++**   **phyloP**                                                
  -------------- ---------------- --------------------- ------------ ------------ ------------ ------------ ------- ---------- ----- ----------- ------- -----------
  1              1                Probably damaging     1            Pathogenic   -2.5         Damaging     0.591   Damaging   5.6   Conserved   7.91    Conserved
  2              /                /                     1            Pathogenic   /            /            /       /          3.9   Conserved   8.998   Conserved
  3              /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  4              /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  5              /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  6              0.993            Probably damaging     1            Pathogenic   -2.79        Damaging     0.704   Damaging   5.6   Conserved   7.799   Conserved
  7              /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  8              /                /                     /            /            /            /            /       /          /     /           /       /
  10             /                /                     /            /            /            /            /       /          /     /           /       /
  13             /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  14             /                /                     1            Pathogenic   /            /            /       /          3.9   Conserved   8.998   Conserved
  16             /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  17             /                /                     /            /            /            /            /       /          /     /           /       /
  18             /                /                     1            Pathogenic   /            /            /       /          3.9   Conserved   3.875   Conserved
  19             /                /                     1            Pathogenic   /            /            /       /          /     /           /       /
  20             /                /                     /            /            /            /            /       /          /     /           /       /

Case No. 8, 10, 17, and 20 are cleavage site mutations.

Mutation of other 13 genes with the exception of LKB1/STK11
-----------------------------------------------------------

In this patient group, 18 types of gene mutations were detected in 9 of 20 cases, all of which were heterozygous mutations (Table [4](#T4){ref-type="table"}). The prediction of protein function change and amino acid evolution conservation caused by the mutations are shown in Table [5](#T5){ref-type="table"} and Table [6](#T6){ref-type="table"}. It is less likely that the *PMS2* mutation in patient No. 3 and 4 and the *AXIN2* mutation in patient No. 7 were pathogenic based on the results of each software.

###### 

Mutation of other 13 genes except *LKB1/STK11* gene

  **Case No**.   **Gene**   ***MMR***            **Type of mutation**                        **Amino acid change**   **Base change**   **New mutation**
  -------------- ---------- -------------------- ------------------------------------------- ----------------------- ----------------- ------------------
  3              *MUTYH*    No                   Missense                                    p.Ala373Val             c.1118C\>T        No
  *MLH1*         Yes        Missense             p.Val384Asp                                 c.1151T\>A              No                
  *PMS2*         Yes        Missense             p.Thr511Met                                 c.1532C\>T              No                
  4              *MSH6*     Yes                  Missense                                    p.Ala1230Gly            c.3689C\>G        Yes
  *MLH1*         Yes        Missense             p.Val384Asp                                 c.1151T\>A              No                
  *PMS2*         Yes        Missense             p.Thr511Met                                 c.1532C\>T              No                
  7              *MLH3*     Yes                  Non-synonymous SNV                          p.Asp1081His            c.3241G\>C        No
  *AXIN2*        No         Non-synonymous SNV   p.Ser738Phe                                 c.2213C\>T              No                
  9              *MSH6*     Yes                  Missense                                    p.Glu1163Val            c.3488A\>T        No
  *APC*          No         Missense             p.Met2221Thr                                c.6662T\>C              No                
  10             *MSH2*     Yes                  Missense                                    p.Ile169Val             c.505A\>G         No
  *MSH6*         Yes        Intron insertion     /                                           c.4001+13C\>CTTAC       Yes               
  *APC*          No         Missense             p.Ala2778Ser                                c.8332G\>T              No                
  14             *MSH2*     Yes                  Missense                                    p.Val89Ala              c.266T\>C         No
  *MSH2*         Yes        Cleavage site        /                                           c.792+1G\>A             Yes               
  *PMS1*         Yes        Nonsense             p.Gln16Ter                                  c.46C\>T                Yes               
  *PMS1*         Yes        Missense             p.Val308Ile                                 c.922G\>A               Yes               
  15             *PTEN*     No                   Missense in 5 \'untranslated region (UTR)   p.Gln171Glu             c.511C\>G         No
  19             *MSH2*     Yes                  Missense                                    p.Leu390Phe             c.1168C\>T        No
  20             *MLH1*     Yes                  Missense                                    p.Arg217Cys             c.649C\>T         No

###### 

Prediction of protein function changes caused by *MSH6* and other gene mutations

  **Case No**.   **Gene**   **Polyphen-2_HDIV**   **Mutation Taster**   **FATHMM**   **M-CAP**                                  
  -------------- ---------- --------------------- --------------------- ------------ -------------- ------- ----------- ------- ----------
  3              *MUTYH*    0.069                 Benign                1            Pathogenic     -2.41   Damaging    0.084   Damaging
  3              *MLH1*     1                     Probably_damaging     1            Pathogenic     -2.66   Damaging    /       /
  3              *PMS2*     0.03                  Benign                1            Polymorphism   1.06    Tolerable   /       /
  4              *MSH6*     1                     Probably_damaging     1            Pathogenic     -2.52   Damaging    0.292   Damaging
  4              *MLH1*     1                     Probably_damaging     1            Pathogenic     -2.66   Damaging    /       /
  4              *PMS2*     0.239                 Benign                1            Polymorphism   1.06    Tolerable   /       /
  7              *MLH3*     1                     Probably_damaging     1            Pathogenic     -2.37   Damaging    0.137   Damaging
  7              *AXIN2*    0.121                 Benign                0.997        Polymorphism   -0.25   Tolerable   /       /
  9              *MSH6*     0.67                  Probably_damaging     1            Pathogenic     -2.12   Damaging    /       /
  9              *APC*      0.156                 Benign                0.737        Pathogenic     -2.47   Damaging    0.046   Damaging
  10             *MSH2*     0                     Benign                1            Polymorphism   -2.29   Damaging    0.028   Damaging
  10             *MSH6*     /                     /                     /            /              /       /           /       /
  10             *APC*      1                     Probably_damaging     1            Pathogenic     -1.53   Damaging    0.033   Damaging
  14             *MSH2*     0.042                 Benign                1            Pathogenic     -2.47   Damaging    0.075   Damaging
  14             *MSH2*     /                     /                     /            /              /       /           /       /
  14             *PMS1*     /                     /                     1            Pathogenic     /       /           /       /
  14             *PMS1*     0.329                 Benign                0.996        Pathogenic     -1.34   Tolerable   0.03    Damaging
  15             *PTEN*     0.956                 Probably_damaging     0.999        Pathogenic     /       /           /       /
  19             *MSH2*     0.148                 Benign                1            Pathogenic     -3.07   Damaging    /       /
  20             *MLH1*     1                     Probably_damaging     1            Pathogenic     -1.91   Damaging    0.247   Damaging

###### 

Prediction of amino acid evolutionary conservation due to mutations in *MSH6* and other genes

  **Case No**.   **Gene**   **GERP++**   **phyloP**             
  -------------- ---------- ------------ -------------- ------- --------------
  3              *MUTYH*    5.67         Conserved      6.955   Conserved
  3              *MLH1*     5.67         Conserved      7.336   Conserved
  3              *PMS2*     -3.23        Nonconserved   -0.25   Nonconserved
  4              *MSH6*     5.5          Conserved      7.481   Conserved
  4              *MLH1*     5.67         Conserved      7.336   Conserved
  4              *PMS2*     -3.23        Nonconserved   -0.25   Nonconserved
  7              *MLH3*     4.6          Conserved      5.502   Conserved
  7              *AXIN2*    2.07         Conserved      2.225   Conserved
  9              *MSH6*     5.23         Conserved      8.923   Conserved
  9              *APC*      6.02         Conserved      3.925   Conserved
  10             *MSH2*     -1.25        Nonconserved   1.857   Nonconserved
  10             *MSH6*     /            /              /       /
  10             *APC*      5.92         Conserved      8.947   Conserved
  14             *MSH2*     3.94         Conserved      3.331   Conserved
  14             *MSH2*     /            /              /       /
  14             *PMS1*     4.99         Conserved      7.805   Conserved
  14             *PMS1*     2.11         Conserved      4.333   Conserved
  15             *PTEN*     /            /              /       /
  19             *MSH2*     4.62         Conserved      1.611   Nonconserved
  20             *MLH1*     5.76         Conserved      2.993   Conserved

Relationship between gene mutation and clinicopathological parameters in patients with PJS
------------------------------------------------------------------------------------------

**Relationship between mutations and family history:** Of the 20 patients in this group, 11 had a family history and 9 had no clear family history. The sequencing results showed the following trend (Figure [1](#F1){ref-type="fig"}): PJS patients with a family history had a higher *LKB1/STK11* mutation rate than those without a family history (81.1% *vs* 77.8%, *P~LKB1/STK11~* = 1.000), and the incidence of *LKB1/STK11* truncation mutations was slightly higher than that in those without a family history (54.5% *vs* 44.4%, *P~truncation\ mutation~ =* 1.000), In addition, the incidence of mutations in other genes was slightly lower than that in those without a family history (27.3% *vs* 66.7%, *P~remaining\ genes~ =* 0.175). However, due to the small sample size in this group, no statistical difference was observed.

![Peak map of *LKB1/STK11* mutation sequencing. The arrow points to the mutation position. "sr" represents reverse sequencing and the remainder is forward sequencing.](WJG-26-1926-g001){#F1}

**Relationship between mutations and age of dark spots:** Of the 20 patients in this group, 11 had black spots aged ≤ 3 years and 9 had black spots aged \> 3 years. The former was referred to as the early-onset group and the latter as the late-onset group. The sequencing results showed the following trend (Figure [1](#F1){ref-type="fig"}): Patients with PJS in the early-onset group had a higher *LKB1/STK11* mutation rate than those in the late-onset group (90.9% *vs* 66.7%, *P~LKB1/STK11~* = 0.285), and the incidence of *LKB1/STK11* truncation mutations was slightly higher than those in the late-onset group (54.5% *vs* 44.4%, *P~mutation~ =* 1.000). In addition, the incidence of mutations in other genes was slightly lower than those in the late-onset group (27.3% *vs* 66.7%, *P~remaining\ genes~* = 0.175). However, due to the small sample size in this group, no statistical difference was observed.

**Relationship between mutation and clinical pathological parameters:** The group was divided according to the presence or absence of *LKB1/STK11* mutations, presence or absence of *LKB1/STK11* truncation mutations, and other gene mutations. The Mann-Whitney *U* test was used to analyze the differences in polyp distribution, polyp load, and internal or surgical intervention. The results showed that the maximum diameter of colorectal polyps was greater in the presence of *LKB1/STK11* mutations (*U =* 32.000, *P =* 0.048), and the others were not statistically different (Table [7](#T7){ref-type="table"}).

###### 

Relationship between gene mutation and clinical pathological parameters

  **Mutation**                       **Result**   **Load of gastric polyps**   **Maximum diameter of gastric polyps (mm)**   **Load of duodenal and small intestinal polyps**   **Maximum diameter of duodenal and small intestinal polyps (mm)**   **Load of Colorectal polyps**   **Maximum diameter of colorectal polyps (mm)**   **Number of hospitalization times**   **Number of operation times**   **Number of intervention times**
  ---------------------------------- ------------ ---------------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------- ------------------------------- ------------------------------------------------ ------------------------------------- ------------------------------- ----------------------------------
  *LKB1/STK11* mutations             *U* value    28.000                       30.000                                        35.500                                             26.000                                                              20.500                          32.000                                           36.000                                49.000                          28.500
  *P* value                          0.885        1.000                        0.442                                         0.878                                              0.734                                                               0.048                           0.750                                            0.122                                 0.750                           
  *LKB1/STK11* truncating mutation   *U* value    62.500                       69.000                                        49.500                                             47.000                                                              23.500                          35.500                                           56.000                                40.500                          35.500
  *P* value                          0.156        0.053                        0.436                                         0.605                                              0.613                                                               0.397                           0.684                                            0.481                                 0.280                           
  Other gene mutations               *U* value    47.500                       42.500                                        39.000                                             36.000                                                              22.000                          19.500                                           38.000                                46.000                          41.500
  *P* value                          0.842        0.842                        0.965                                         0.762                                              0.607                                                               0.388                           0.412                                            0.824                                 0.552                           

Follow-up
---------

All patients of this study were followed-up to January 10, 2020. The final follow-up age was 25.9 ± 15.307 years, and the oldest patient was 47 years. The time span from the patient\'s first admission was 8.9 ± 8.837 years. Five of these patients were re-admitted to our hospital for a total of 14 colonoscopy examinations and treatments.

DISCUSSION
==========

In this patient group, 80.0% (16/20) of PJS cases were found to have *LKB1/STK11* mutations in hamartoma polyps, consistent with previous reports\[[@B13]-[@B15]\]. In addition, 9 patients (45.0%) also had 18 types of mutations in other genes. The total incidence of mutations in this group of patients was 90.0% (18/20). Among them, *LKB1/STK11* gene: c.243delG, c.363_364delGA, c.722delC, c.144_145insGCAAG, c.454_455insC, c.464+1G\>T, c.464+1G\>A, c.598-1G\>A, *MSH2:* C.792+1G\>A, *MSH6:* c.3689C\>G, c.4001+13C\>CTTAC, *PMS1:* c.46C\>T, and c.922G\>A are newly discovered mutations, which suggest that the genetic mutations in PJS hamartoma polyp tissue are complex and diverse. In addition, we found that the cases with mutations in the exon 5 of *LKB1/STK11* gene were all in the early-onset group and the cases with splice site mutations in the exon 3 were all in the late-onset group. Those with negative *LKB1/STK11* mutations but carrying other gene mutations were all in the late-onset group. This suggests that different clinical phenotypes of PJS may have a different molecular genetics basis. This is worth further study.

The clinical phenotypic heterogeneity of PJS is obvious. With the continuous improvement in gene detection technology, the relationship between genotype and clinical phenotype has become a focus. However, PJS has scattered populations and relatively few cases as it is also a very rare disease in the clinic. A lot of research has been carried out at home and abroad, but no consensus has been reached on the relationship between genotypes and clinical phenotypes. Although this study did not detect a statistically significant mutation frequency in patients with or without a family history due to the small sample size, we found that the colorectal polyps with *LKB1/STK11* mutations were larger (*U* = 32.000, *P* = 0.048). There was no statistically significant relationship between whether *LKB1/STK11* gene was mutated and whether it was a truncation mutation and the patient\'s polyp distribution, polyp load, polyp size, and medical or surgical intervention. Some studies have demonstrated that MLPA assay technology can improve the detection rate in *LKB1/STK11* gene mutation screening in PJS patients\[[@B16]\]. If the MLPA assay is performed in patients with negative mutations, there may be new findings. However, we also found that two patients with *LKB1/STK11* gene exon 5 anterior and posterior splicing site mutations had early-onset of pigment spots, and two patients with cleavage site mutations in exon 3 had late-onset of pigment spots, and patients without *LKB1/STK11* gene mutations but with other gene mutations all had late-onset of pigment spots. Limited by the sample size in this study, there was no statistical difference between the two groups, and we may be able to uncover the molecular genetic mechanism of clinical subtypes if the sample size is increased in further studies.

In addition, the mutation rate of *LKB1/STK11* gene in PJS patients has not reached 100% using various sequencing techniques, which may be related to the limitations of current technology, but it is more likely to suggest that PJS is a heterogeneous genetic disease, or that there are signaling pathways related to its development and progression. Moreover, we also found that there were other gene mutations in the PJS hamartoma polyp tissue, in which the *DNA mismatch repair* (*MMR*) gene is particularly prominent (accounting for 88.9% of all other gene mutations). According to a variety of software predictions, 81.8% (9/11) of them may be pathogenic and conservative in amino acid evolution. These may be the inherent genetic mechanism of the clinical phenotypic heterogeneity of PJS. The MMR system mainly includes proteins such as hMLH1, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2, which maintain gene stability mainly by repairing mismatched bases and insertion/deletion loops in DNA synthesis\[[@B17]-[@B19]\]. Among them, MSH2 and MSH6, MSH2 and MSH3 constitute MutSα and MutSβ, respectively. The former can recognize single base mismatch and insertion/deletion loops, and the latter can recognize 2-8 base insertion/deletion loops. However, MutLα and MutLβ are composed of MLHL with PMS2 and PMSL, and their functions are to localize the mismatch site, cooperate with Exo I, proliferating cell nuclear antigen, and DNA polymerase to remove base mismatches and resynthesize the correct DNA\[[@B20]\]. Functional alterations in MMR may cause microsatellite instability, which can be found in sporadic and hereditary tumors in various tissues\[[@B21]-[@B23]\], and have clear guiding significance for prognosis and drug efficacy prediction in colorectal cancer patients. In particular, only *MSH6* mutation was detected in the PJS hamartoma polyps without *LKB1/STK11* mutation. This also indicates that there may be other mechanisms besides *LKB1/STK11* involved in the occurrence, development and malignant transformation of PJS hamartoma polyps. Therefore, we consider that destruction of the MMR system may play an important role in the development course of some PJS patients, and with the continuous accumulation of DNA replication errors, it leads to an increased risk of malignant transformation in various tissues and organs. This is worthy of further study.

It was reported that the risk of intussusception in PJS patients was 50% at age 20 years, the incidence of intestinal intussusception was 95%, and 80% of intussusceptions manifested as acute abdomen and 92.5% of cases were treated with surgery\[[@B5]\]. All patients in the present group did not experience intestinal obstruction, intussusception or other gastrointestinal emergencies and malignant changes of polyps during the follow-up period, and did not undergo surgical treatment. We believe that high-frequency enteroscopy and microscopic treatment effectively alleviate the progress of the disease and prolong the patient\'s survival.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant genetic disease, which belongs to the category of hereditary colorectal cancer. It is currently believed that the occurrence of PJS is closely related to mutations in the *LKB1/STK11* gene, and that different types of mutations have different effects on clinical phenotype. The genetic heterogeneity of PJS is obvious, and no other pathogenic genes have been found except the *STK11* gene, and the relationship between genotype and phenotype is not clear.

Research motivation
-------------------

This study aimed to investigate the mutation status of hereditary colorectal tumor-associated genes in hamartoma polyp tissue of PJS and discuss its relationship with the clinicopathological data of PJS.

Research objectives
-------------------

To investigate mutations in genetically-related genes, try to explain the genetic heterogeneity of the disease, and investigate whether the disease has a relatively clear genotype-phenotype relationship.

Research methods
----------------

Twenty patients with PJS were randomly selected for this study who were treated in the Air Force Medical Center and their clinicopathological data were collected, including family history, polyp distribution, polyp load, and internal or surgical intervention. Next-generation sequencing technology was used to study the mutation status of the genetically-related genes in PJS hamartoma polyp tissues, and examine the relationship between the mutation status of these genes and the clinical pathological data of PJS.

Research results
----------------

*LKB1/STK11* gene mutations were detected in 16 of 20 cases, with 14 types of mutations, among which 8 new mutations were detected. 18 types of other gene mutations were detected in 9 of these 20 cases, all of which were heterozygous mutations. There was no statistical difference between mutations and family history, and between mutations and blackspot age. The maximum diameter of colorectal polyps was greater in the presence of *LKB1*/*STK11* mutations.

Research conclusions
--------------------

We found a series of gene mutation types in hamartoma polyp tissues of PJS patients, and destruction of the MMR system may play an important role in the development course of some PJS patients. The colorectal hamartoma polyps with *LKB1/STK11* mutations were larger than those with other gene mutations.

Research perspectives
---------------------

Improvements in gene sequencing technology and the identification of new mutation sites of *STK11* and other possible pathogenic genes are necessary to describe the pathogenesis of PJS at the genetic level. In addition, an investigation into whether the disease has a relatively clear genotype-phenotype relationship is a hot spot for future research.
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